Global spending on orphan drugs in France, Germany, the UK, Italy and Spain during 2007.
about
Reimbursement of orphan drugs in Belgium: what (else) matters?Shining a light in the black box of orphan drug pricingRare diseases and orphan drugs: Latvian storyOrphan drugs expenditure in the Netherlands in the period 2006-2012.Developing and paying for medicines for orphan indications in oncology: utilitarian regulation vs equitable care?Can the EVIDEM Framework Tackle Issues Raised by Evaluating Treatments for Rare Diseases: Analysis of Issues and Policies, and Context-Specific Adaptation.Unintended effects of orphan product designation for rare neurological diseases.Paying for the Orphan Drug System: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments?Impact of orphan drugs on Latvian budget.Sustainable rare diseases business and drug access: no time for misconceptions.Reconciling uncertainty of costs and outcomes with the need for access to orphan medicinal products: a comparative study of managed entry agreements across seven European countries.Estimating the budget impact of orphan drugs in Sweden and France 2013-2020.Estimating the budget impact of orphan medicines in Europe: 2010 - 2020.Drugs for rare diseases: influence of orphan designation status on price.Market uptake of orphan drugs--a European analysis.Incremental cost per quality-adjusted life year gained? The need for alternative methods to evaluate medical interventions for ultra-rare disorders.
P2860
Q30587491-11F5A049-1B87-4A80-AF7D-24CEBF1C490BQ33602241-08888B44-2615-4F9F-BAF8-0E853A7529FFQ34234365-7E70A44C-FA02-4596-AB7D-7243741E65BEQ34333608-895CA021-D14F-46A8-BD25-18D997D42840Q35653897-01B93025-B601-44A4-A345-56F058392262Q35835153-786C67A7-A1E6-49B1-B2A8-8A4D3B3E19ADQ36375543-631391BC-E0E8-4554-8CCF-300DE7444279Q36639084-71BD60A7-B42B-4694-A162-1D503B46B265Q36895393-4CFC3083-173D-4701-B0E3-69DC215E4D16Q37075327-5C1A832D-8721-4809-BCA6-4E1E9340ADF8Q37441285-D4E89FBF-8B34-4A4D-A283-D23F3ADA231DQ37595752-B9DB728B-FB4F-43BE-B79D-A4527910035DQ38680339-B81AD1B2-8ECB-4E8C-A132-968F7C8820DDQ39738172-5DF0BBB2-C3A7-4215-8EC1-62DC703290CDQ44305532-5E7C0348-8995-403A-A785-BF2DB3C2ED75Q47571494-600353C6-46B8-4B05-897D-FF312AB9B6B9
P2860
Global spending on orphan drugs in France, Germany, the UK, Italy and Spain during 2007.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Global spending on orphan drugs in France, Germany, the UK, Italy and Spain during 2007.
@en
Global spending on orphan drugs in France, Germany, the UK, Italy and Spain during 2007.
@nl
type
label
Global spending on orphan drugs in France, Germany, the UK, Italy and Spain during 2007.
@en
Global spending on orphan drugs in France, Germany, the UK, Italy and Spain during 2007.
@nl
prefLabel
Global spending on orphan drugs in France, Germany, the UK, Italy and Spain during 2007.
@en
Global spending on orphan drugs in France, Germany, the UK, Italy and Spain during 2007.
@nl
P2093
P1476
Global spending on orphan drugs in France, Germany, the UK, Italy and Spain during 2007.
@en
P2093
Itziar Oyagüez
Javier Orofino
Javier Soto
Miguel A Casado
P304
P356
10.2165/11531880-000000000-00000
P577
2010-01-01T00:00:00Z
P6179
1030987555